- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. Request a Demo or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 549-563 of
973 results
1093 Exhibit: Beel Declaration
Document
IPR2023-00724, No. 1093 Exhibit - Beel Declaration (P.T.A.B. Dec. 18, 2023)
|
|
Cite Document
2539 Exhibit: EX2539 Notice of Service, In re Ozempic Semaglutide Patent Litigatio...
Document
IPR2023-00724, No. 2539 Exhibit - EX2539 Notice of Service, In re Ozempic Semaglutide Patent Litigation, No 122 md 03038 CFC Dkt 330 (P.T.A.B. Jul. 31, 2024)
|
|
Cite Document
... Dr John Bantle Regarding In validity of US Patent No 10,335,462, In re Ozempic Semag lutide Patent Litigation, No 1...
Document
IPR2023-00724, No. 2650 Exhibit - EX2650 Excerpt of Reply Expert Report of Dr John Bantle Regarding In validity of US Patent No 10,335,462, In re Ozempic Semag lutide Patent Litigation, No 122 cv 03
|
|
Cite Document
2090 Exhibit: EX2090 Cosentino, F et al, ESC Guidelines on diabetes, pre diabetes...
Document
IPR2023-00724, No. 2090 Exhibit - EX2090 Cosentino, F et al, ESC Guidelines on diabetes, pre diabetes, and cardiovascular diseases developed in collaboration with the EASD, Eur Heart J, 41...
|
|
Cite Document
2368 Exhibit: EX2368 Tomkin, GH, Treatment of type 2 diabetes, lifestyle, GLP1 ag...
Document
IPR2023-00724, No. 2368 Exhibit - EX2368 Tomkin, GH, Treatment of type 2 diabetes, lifestyle, GLP1 agonists and DPP4 inhibitors, World J Diabetes, 2014 Oct 15 55636 650 (P.T.A.B. Jan. 17...
|
|
Cite Document
2017 Exhibit: EX2017 Novo Nordisk Company Announcement October 10, 2023
Document
IPR2023-00724, No. 2017 Exhibit - EX2017 Novo Nordisk Company Announcement October 10, 2023 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2460 Exhibit: EX2460 US Food Drug Administration, DrugsFDA, Xultophy 10036
Document
IPR2023-00724, No. 2460 Exhibit - EX2460 US Food Drug Administration, DrugsFDA, Xultophy 10036 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
1048 Exhibit: FDA Exposure Response 2003
Document
IPR2023-00724, No. 1048 Exhibit - FDA Exposure Response 2003 (P.T.A.B. Mar. 16, 2023)
|
|
Cite Document
2415 Exhibit: EX2415 US Food Drug Administration, DrugsFDA, Tradjenta®
Document
IPR2023-00724, No. 2415 Exhibit - EX2415 US Food Drug Administration, DrugsFDA, Tradjenta® (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
1114 Exhibit: Exhibit 1114 Buse
Document
IPR2023-00724, No. 1114 Exhibit - Exhibit 1114 Buse (P.T.A.B. May. 22, 2024)
|
|
Cite Document
1130 Exhibit: Exhibit 1130 Novo Nordisk Annual Report 2011
Document
IPR2023-00724, No. 1130 Exhibit - Exhibit 1130 Novo Nordisk Annual Report 2011 (P.T.A.B. May. 22, 2024)
|
|
Cite Document
1135 Exhibit: Exhibit 1135 40th Orange Book
Document
IPR2023-00724, No. 1135 Exhibit - Exhibit 1135 40th Orange Book (P.T.A.B. May. 22, 2024)
|
|
Cite Document
2470 Exhibit: EX2470 Rybelsus Prescribing Information rev Jan 2020
Document
IPR2023-00724, No. 2470 Exhibit - EX2470 Rybelsus Prescribing Information rev Jan 2020 (P.T.A.B. Jan. 17, 2024)
|
|
Cite Document
2654 Exhibit: EX2654 July 10, 2024 Email Thread Among Counsel for Petitioners M...
Document
IPR2023-00724, No. 2654 Exhibit - EX2654 July 10, 2024 Email Thread Among Counsel for Petitioners Mylan, DRL, and Sun, and Counsel for Novo Regarding IPR2023 00724 – Service of draft ...
|
|
Cite Document
1088 Exhibit: Exhibit 1088
Document
IPR2023-00724, No. 1088 Exhibit - Exhibit 1088 (P.T.A.B. Aug. 10, 2023)
|
|
Cite Document
